Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (19 quarters reported)
$187M in Q4 2021 → $1.81B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| CT Celldex Therapeutics Inc New | 10.9% | Trimmed 8.9% | 5,322,908 | $198M |
| Syndax Pharmaceuticals Inc | 9.7% | Unchanged | 8,050,959 | $176M |
| Vaxcyte Inc | 9.4% | Unchanged | 2,922,335 | $170M |
| Cogent Biosciences Inc | 7.8% | Trimmed 9.2% | 3,667,097 | $142M |
| Vera Therapeutics Inc | 6.9% | Trimmed 15% | 2,890,059 | $124M |
| Viridian Therapeutics Inc | 6.6% | Added 176% | 6,453,877 | $119M |
| Travere Therapeutics Inc | 6.3% | Added 27% | 2,000,000 | $114M |
| Beam Therapeutics Inc | 5.4% | Trimmed 23% | 2,840,792 | $97.5M |
| Urogen Pharma Ltd | 5.0% | Added 8.3% | 2,434,207 | $89.6M |
| Legend Biotech Corp | 4.8% | Added 90% | 3,001,205 | $86.7M |
| Cytomx Therapeutics Inc. | 4.5% | Added 45% | 21,703,093 | $81.4M |
| Relay Therapeutics Inc | 3.4% | Added 132% | 3,300,000 | $61.7M |
| Cullinan Therapeutics Inc | 3.1% | Unchanged | 3,114,132 | $56.7M |
| Mbx Biosciences Inc | 2.9% | Unchanged | 934,799 | $51.6M |
| IH Immunocore Hldgs PLC | 2.4% | Added 55% | 1,375,000 | $43.7M |
| Nurix Therapeutics Inc | 1.6% | Unchanged | 1,194,757 | $29M |
| Sutro Biopharma Inc | 1.6% | Unchanged | 872,558 | $29M |
| Biocryst Pharmaceuticals Inc | 1.4% | Trimmed 56% | 2,522,660 | $25.2M |
| Pharvaris N V | 1.3% | Added 3.3% | 661,795 | $22.9M |
| Summit Therapeutics Inc | 1.0% | New | 1,200,000 | $17.5M |
| Prelude Therapeutics Inc | 0.7% | Added 52% | 2,415,087 | $12.9M |
| Insmed Inc | 0.6% | New | 100,000 | $10.7M |
| Burning Rock Biotech Ltd | 0.6% | Added 0.9% | 1,238,563 | $10.5M |
| Geron Corp | 0.5% | Unchanged | 6,836,318 | $8.75M |
| Amarin Corp PLC | 0.5% | Added 13% | 532,982 | $8.5M |
| Alector Inc | 0.4% | Added 90% | 3,808,494 | $7.66M |
| PM Parabilis Medicines Inc | 0.4% | New | 250,000 | $6.84M |
| Caribou Biosciences Inc | 0.2% | Unchanged | 2,503,302 | $4.41M |
| PT Proqr Thrapeutics N V | 0.2% | Unchanged | 1,566,317 | $2.91M |
| Candel Therapeutics Inc | 0.1% | Trimmed 52% | 96,741 | $996K |
| Engene Therapeutics Inc | 0.0% | New | 457,855 | $792K |
| Traws Pharma Inc | 0.0% | New | 84,400 | $71.2K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Viridian Therapeutics Inc | Added | +4,112,225 | +$75.5M | 6.6% |
| Legend Biotech Corp | Added | +1,424,910 | +$41.2M | 4.8% |
| Kalvista Pharmaceuticals Inc | Exited | −1,820,954 | −$36.7M | — |
| Relay Therapeutics Inc | Added | +1,875,741 | +$35.1M | 3.4% |
| Apellis Pharmaceuticals Inc | Exited | −825,000 | −$33.2M | — |
| Biocryst Pharmaceuticals Inc | Trimmed | −3,158,135 | −$31.6M | 1.4% |
| Beam Therapeutics Inc | Trimmed | −841,393 | −$28.9M | 5.4% |
| Cytomx Therapeutics Inc. | Added | +6,690,000 | +$25.1M | 4.5% |
| Travere Therapeutics Inc | Added | +430,982 | +$24.5M | 6.3% |
| Travere Therapeutics Inc | Exited | −800,000 | −$23.8M | — |
Showing the 10 largest of 35 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cogent Biosciences Inc | Trimmed | −2,127,892 | −$81.9M | 9.6% |
| Tyra Biosciences Inc | Exited | −1,564,492 | −$41.1M | — |
| Urogen Pharma Ltd | New | +2,247,393 | +$40.4M | 2.5% |
| Cg Oncology Inc | Exited | −945,830 | −$39.3M | — |
| Biocryst Pharmaceuticals Inc | Trimmed | −3,685,731 | −$35.1M | 3.3% |
| Travere Therapeutics Inc | Added | +1,051,134 | +$31.2M | 2.9% |
| Beam Therapeutics Inc | Added | +1,241,971 | +$29.6M | 5.4% |
| Legend Biotech Corp | New | +1,576,295 | +$28.5M | 1.8% |
| Cytomx Therapeutics Inc. | Added | +6,047,016 | +$28.4M | 4.4% |
| Beam Therapeutics Inc | Exited | −937,000 | −$26M | — |
Showing the 10 largest of 33 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Viridian Therapeutics Inc | Trimmed | −2,957,386 | −$92M | 2.9% |
| Cogent Biosciences Inc | Trimmed | −1,720,949 | −$61.1M | 14.0% |
| Cg Oncology Inc | Trimmed | −1,059,375 | −$44M | 2.5% |
| Wave Life Sciences Ltd | Trimmed | −2,390,948 | −$40.6M | 2.4% |
| Mbx Biosciences Inc | Trimmed | −1,065,201 | −$33.6M | 1.9% |
| EH Engene Holdings Inc | Trimmed | −3,501,192 | −$31.6M | 0.9% |
| Vera Therapeutics Inc | Trimmed | −594,749 | −$30.1M | 11.1% |
| Beam Therapeutics Inc | New | +937,000 | +$26M | 1.7% |
| Cytomx Therapeutics Inc | Added | +5,319,574 | +$22.7M | 2.4% |
| Tyra Biosciences Inc | Trimmed | −765,506 | −$20.1M | 2.6% |
Showing the 10 largest of 39 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mbx Biosciences Inc | New | +2,000,000 | +$35M | 2.6% |
| UT United Therapeutics Corp Del | New | +67,588 | +$20M | 1.5% |
| Apellis Pharmaceuticals Inc | New | +808,607 | +$18.3M | 1.4% |
| Cg Oncology Inc | Trimmed | −452,462 | −$18.2M | 6.0% |
| Vera Therapeutics Inc | Added | +600,913 | +$17.5M | 8.7% |
| Pharvaris N V | New | +675,000 | +$16.8M | 1.3% |
| Travere Therapeutics Inc | Trimmed | −590,964 | −$14.1M | 1.7% |
| Nurix Therapeutics Inc | Added | +995,000 | +$9.19M | 1.5% |
| Urogen Pharma Ltd | Trimmed | −374,161 | −$9.19M | 0.5% |
| Cogent Biosciences Inc | Trimmed | −606,385 | −$8.71M | 8.4% |
Showing the 10 largest of 17 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Natera Inc | Exited | −1,167,570 | −$165M | — |
| Vera Therapeutics Inc | Added | +1,026,887 | +$24.2M | 8.7% |
| IH Immunocore Hldgs PLC | Trimmed | −719,309 | −$22.6M | 3.3% |
| Soleno Therapeutics Inc | Exited | −302,500 | −$21.6M | — |
| Legend Biotech Corp | Exited | −610,000 | −$20.7M | — |
| Amarin Corp PLC | New | +576,111 | +$9.34M | 1.0% |
| Urogen Pharma Ltd | Added | +631,573 | +$8.65M | 1.0% |
| CT Celldex Therapeutics Inc New | Trimmed | −399,271 | −$8.13M | 13.4% |
| Amarin Corp PLC | Exited | −12,414,628 | −$5.56M | — |
| Liquidia Corporation | Trimmed | −433,755 | −$5.4M | 0.3% |
Showing the 10 largest of 32 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | Exited | −300,000 | −$176M | — |
| Natera Inc | Trimmed | −854,528 | −$121M | 13.9% |
| Dynavax Technologies Corp | Trimmed | −3,940,038 | −$51.1M | 2.9% |
| Vaxcyte Inc | Added | +863,204 | +$32.6M | 10.2% |
| CT Celldex Therapeutics Inc New | Added | +1,435,793 | +$26.1M | 9.9% |
| Liquidia Corporation | Trimmed | −1,632,526 | −$24.1M | 0.8% |
| Vera Therapeutics Inc | Added | +942,090 | +$22.6M | 4.8% |
| Soleno Therapeutics Inc | New | +302,500 | +$21.6M | 1.8% |
| Legend Biotech Corp | New | +610,000 | +$20.7M | 1.7% |
| Viridian Therapeutics Inc | Added | +1,373,738 | +$18.5M | 5.3% |
Showing the 10 largest of 28 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | New | +300,000 | +$176M | 10.4% |
| Vaxcyte Inc | Added | +1,297,508 | +$106M | 11.3% |
| CT Celldex Therapeutics Inc New | Added | +1,605,598 | +$40.6M | 7.6% |
| IH Immunocore Hldgs PLC | New | +1,225,576 | +$36.2M | 2.1% |
| Syndax Pharmaceuticals Inc | Added | +2,677,075 | +$35.4M | 6.7% |
| Dynavax Technologies Corp | Trimmed | −1,771,852 | −$22.6M | 5.0% |
| EH Engene Holdings Inc | Added | +3,257,863 | +$21.7M | 2.0% |
| Cg Oncology Inc | Added | +748,900 | +$21.5M | 4.3% |
| Viridian Therapeutics Inc | Added | +814,967 | +$15.6M | 3.8% |
| Cullinan Therapeutics Inc | New | +1,252,738 | +$15.3M | 0.9% |
Showing the 10 largest of 25 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | Trimmed | −300,000 | −$140M | 1.1% |
| SS SPDR S&P 500 ETF Tr | Exited | −200,000 | −$109M | — |
| Insmed Inc | Exited | −1,000,000 | −$67M | — |
| Cg Oncology Inc | Added | +1,716,894 | +$64.8M | 5.1% |
| Vaxcyte Inc | Added | +286,048 | +$32.7M | 9.1% |
| Beam Therapeutics Inc | New | +1,302,085 | +$31.9M | 2.4% |
| Viridian Therapeutics Inc | Added | +761,295 | +$17.3M | 4.4% |
| Protagonist Therapeutics Inc | Trimmed | −343,631 | −$15.5M | 1.6% |
| Dynavax Technologies Corp | Added | +1,250,125 | +$13.9M | 7.1% |
| Liquidia Corporation | Added | +1,349,754 | +$13.5M | 1.7% |
Showing the 10 largest of 27 changes.
Loading...
